[ad_1]
Some countries have approved Covid-19 booster injections to boost people’s immunity
According to the test data released by the manufacturer on Thursday, the booster injection of the anti-Covid-19 vaccine developed by Pfizer/BioNTech is 95.6% effective against symptomatic infections.
The two companies said in a statement that the Phase III clinical trial of “10,000 participants 16 years and older” showed that “during the Delta virus epidemic, the relative effectiveness of the vaccine against the disease is 95.6%.”
The study showed the “preliminary results” of the enhanced trial, and the third dose of the vaccine showed “good safety.”
Pfizer CEO Albert Bourla said: “These results further demonstrate the benefits of boosters, because our goal is to protect people from this disease.”
The two companies said in their statements that preliminary results will be shared with regulators “as soon as possible.”
According to some studies, some countries have approved Covid-19 booster injections to improve the immunity of people who have been vaccinated, but their protection may decline after a few months.
In the United States, the Federal Food and Drug Administration (FDA) approved the third dose in September for everyone 65 years and older, as well as people at high risk of severe Covid.
Please also read:
>> Dubai announced that Pfizer injected boosters for some residents
>> UAE: Sputnik, Pfizer Covid vaccine enhancement agreement, qualification announced
The European Medicines Agency (EMA) approved a booster for people over the age of 18 in early October, allowing national regulators to decide which groups should be eligible first.
In Israel, the authorities went one step further and approved booster injections for everyone 12 years and older.
[ad_2]
Source link